secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biostax Corp. (—)
CIK:        0001559356
Form:       8-K
Filed at:   2023-10-24T23:59:59+00:00
Accession:  0001493152-23-038052
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostax Corp (f/k/a Immune Therapeutics) name change to BTAX approved; pivots to substance abuse & HIV
--------------------------------------------------------------------------------

- Name change from Immune Therapeutics, Inc. to Biostax Corp effective Oct 5, 2023; FINRA approved Oct 20.
- New ticker symbol BTAX on OTC Pink Markets; old stock certificates remain valid.
- Strategic pivot to commercialize substance abuse solutions internationally and advance HIV treatment.
- Combining naltrexone technology with Immgenuity's IMTV014 vaccine platform for HIV/NeuroAIDS.
- CEO Noreen Griffin signals future commercial partnership updates and website launch in coming quarters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559356/000149315223038052/0001493152-23-038052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559356/000149315223038052/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer